Standout Papers

Two Phase 3 Trials of Lebrikizumab for Moderate-to-Severe Atopic Dermatitis 2022 2026 2023 2024138
  1. Two Phase 3 Trials of Lebrikizumab for Moderate-to-Severe Atopic Dermatitis (2023)
    Jonathan I. Silverberg, Emma Guttman‐Yassky et al. New England Journal of Medicine
  2. Two Phase 3, Randomized, Controlled Trials of Ruxolitinib Cream for Vitiligo (2022)
    David Rosmarin, Thierry Passeron et al. New England Journal of Medicine

Immediate Impact

3 by Nobel laureates 21 from Science/Nature 66 standout
Sub-graph 1 of 22

Citing Papers

Nociceptive neurons promote gastric tumour progression via a CGRP–RAMP1 axis
2025 StandoutNature
Atopic dermatitis
2025 Standout
7 intermediate papers

Works of Julien Sénéschal being referenced

Two Phase 3 Trials of Lebrikizumab for Moderate-to-Severe Atopic Dermatitis
2023 Standout
Vitiligo Skin Is Imprinted with Resident Memory CD8 T Cells Expressing CXCR3
2017
and 2 more

Author Peers

Author Last Decade Papers Cites
Julien Sénéschal 1245 1356 1705 160 3.6k
Reinhart Speeckaert 727 1470 1260 142 3.9k
Ortonne Jp 1333 621 1253 133 2.9k
J.‐P. Ortonne 1479 504 1974 69 3.3k
J.L.M. Hawk 2235 637 883 115 3.6k
Beate M. Czarnetzki 1322 776 2017 184 4.9k
Katia Boniface 1473 938 4458 62 6.3k
Joseph G. Morelli 1371 871 399 120 3.6k
Fujio Otsuka 1219 492 1397 178 5.3k
Mamitaro Ohtsuki 3274 609 3614 183 6.5k
P.E. Hutchinson 1318 341 900 84 3.0k

All Works

Loading papers...

Rankless by CCL
2026